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OBJECTIVEdThis multicenter, open-label, parallel-arm study compared the efﬁcacy and
safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2
diabetes inadequately controlled with metformin (with or without sulfonylureas).
RESEARCH DESIGN ANDMETHODSdPatients were randomized to EQW (2 mg) or
detemir (once or twice daily, titrated to achieve fasting plasma glucose #5.5 mmol/L) for 26
weeks. The primary outcome was proportion of patients achieving A1C#7.0% and weight loss
$1.0 kg at end point, analyzed by means of logistic regression. Secondary outcomes included
measures of glycemic control, cardiovascular risk factors, and safety and tolerability.
RESULTSdOf 216 patients (intent-to-treat population), 111 received EQW and 105 received
detemir. Overall, 44.1% (95% CI, 34.7–53.9) of EQW-treated patients compared with 11.4%
(6.0–19.1) of detemir-treated patients achieved the primary outcome (P , 0.0001). Treatment
with EQW resulted in signiﬁcantly greater reductions than detemir in A1C (least-square mean6
SE,21.306 0.08% vs.20.886 0.08%; P, 0.0001) and weight (22.76 0.3 kg vs. +0.86 0.4
kg; P, 0.0001). Gastrointestinal-related and injection site–related adverse events occurredmore
frequently with EQW than with detemir. There was no major hypoglycemia in either group. Five
(6%) patients in the EQW group and six (7%) patients in the detemir group experienced minor
hypoglycemia; only one event occurred without concomitant sulfonylureas (detemir group).
CONCLUSIONSdTreatment with EQW resulted in a signiﬁcantly greater proportion of
patients achieving target A1C and weight loss than treatment with detemir, with a low risk of
hypoglycemia. These results suggest that EQW is a viable alternative to insulin detemir treatment
in patients with type 2 diabetes with inadequate glycemic control using oral antidiabetes drugs.
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Type 2 diabetes is a chronic, progres-sive disease associated with obesitythat requires multiple interventions
to maintain long-term glycemic control
(1). Thus, treatments that improve both hy-
perglycemia and body weightdwith a low
risk of hypoglycemiadmay be more de-
sirable in the treatment of type 2 diabetes
than treatments associated with weight
gain. Over time, many patients do not
achieve adequate glycemic control with
oral antidiabetes drugs (OADs) and
additional therapies are required to achieve
A1C targets of #6.5% (2) or #7% (1,3).
After OADs (i.e.,metformin) fail or if OADs
are contraindicated, algorithms recom-
mend the use of add-on therapies including
insulin or glucagon-like peptide-1 (GLP-1)
receptor agonists (1,2,4).
Exenatide once weekly (EQW), the
extended-release formulation of exena-
tide, is a GLP-1 receptor agonist approved
for use in the United States and Europe to
improve glycemic control in adults with
type 2 diabetes. EQW administered by
subcutaneous injection has been shown
to provide sustained glycemic control and
does not have the undesirable effects of
weight gain and hypoglycemia that are
typically associated with insulin and some
OADs (5–8). Further,weeklydosingmay im-
prove adherence to treatment, as suggested
by improvements in patient-reported out-
comes (9) and therefore may improve
therapeutic outcomes (10).
At present, there have been no com-
parisons between EQW or other GLP-1
receptor agonists and insulin detemir,
which is the most weight-neutral, long-
acting insulin available (11). Compared
with other basal insulin regimens (e.g.,
NPH insulin and insulin glargine), insulin
detemir produced similar or greater im-
provements in glycemic control, was as-
sociated with less weight gain, and, in
some trials, was associated with fewer
events of hypoglycemia (12–15).
This study is the ﬁrst to compare
EQW and insulin detemir (administered
once or twice daily) with respect to
glycemic control, body weight, lipids,
safety, tolerability, and patient-reported
outcomes in patients with type 2 diabetes
whose diabetes was inadequately con-
trolled with OADs.
RESEARCH DESIGN AND
METHODS
Study design
This 30-week (4-week screening and 26-
week intervention), phase 3, multicenter,
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randomized, open-label, parallel-arm,
active-comparator study (NCT01003184)
was conducted in patients with type 2
diabetes not achieving adequate glycemic
control using metformin or a combination
of metformin and a sulfonylurea (SU).
Patients were randomized in a 1:1 ratio to
exenatide 2 mg subcutaneous injection
once weekly or insulin detemir injection
once daily or twice daily (BID) for 26
weeks, in addition to continuing current
OAD therapy.
Detemir was initiated as once daily
and titrated according to manufacturer
labeling and a published “treat-to-target”
titration algorithm described by Holman
et al. (15,16), with an aim of target fasting
plasma glucose (FPG) concentrations of
,5.5 mmol/L (,99 mg/dL) before
breakfast and before dinner. Patients ini-
tiated treatment using calculations de-
scribed in the algorithm (15,16) and
then titrated their doses weekly, as in-
structed by the investigator, based on daily
self-monitored capillary fasting blood glu-
cose measurements. Detemir dosages
were reduced if hypoglycemia occurred
or if the patient had a blood glucose mea-
surement of,3.9mmol/L (,70.2mg/dL).
Patients added an insulin injection before
breakfast if glucose readings were at target
before breakfast but not before the even-
ing meal (and if nocturnal hypoglycemia
limited an increase in dosage before
bedtime).
Randomization was stratiﬁed accord-
ing to baseline A1C level [$7.0 to,8.5%
($53 to 69 mmol/mol) or $8.5 to
#10.0% ($69 to #86 mmol/mol)] and
SU use, and was centrally determined by a
computer-generated random sequence
using an interactive voice-response sys-
tem. Oral metformin therapy was contin-
ued unchanged, whereas SU dosages were
reduced by 50% at initiation of study
treatment and further reduced or discon-
tinued if hypoglycemia occurred or if A1C
#7.0% (#53 mmol/mol) was achieved.
This study was conducted in accor-
dance with applicable laws and regula-
tions, appropriate Ethical Review Board
consents, and the International Confer-
ence on Harmonization guideline on
good clinical practice and ethical princi-
ples established by the Declaration of
Helsinki (17). All patients provided writ-
ten informed consent.
Study population
Eligible patients were at least 18 years of
age with type 2 diabetes and had A1C
levels $7.1 to #10.0% ($54 to #86
mmol/mol) despite use of OAD, BMI of
25 kg/m2 to 45 kg/m2, and stable weight
(#5% variability) for 3 months. Patients
were required to be using a stable dose of
metformin ($1,000 mg/day) alone or in
combination with a stable dose of SU (as a
separate formulation) for at least 3 months
before randomization.
Women of childbearing potential
were ineligible unless using a reliable
form of contraception throughout the
study. Patients were excluded if they
had a clinically signiﬁcant medical con-
dition that could preclude safe participa-
tion in this study, had more than three
major hypoglycemic episodes in the past
6 months, or had been treated with a drug
that promotes weight loss within 3
months of screening. Lipid-lowering and
antihypertensive medications were al-
lowed with appropriate dose adjustments
(per investigator decision).
Interventions
Patients performed 7-point self-moni-
tored blood glucose proﬁles at baseline
and again between weeks 18 and 26. At
baseline and week 26 (or the early termi-
nation visit for patients who discontinued
before week 26), blood samples were
taken to measure A1C, FPG, fasting
plasma lipids, and other cardiovascular
risk markers. Body weight, waist circum-
ference, and vital signs were measured at
each study visit.
Episodes of hypoglycemia, adverse
events (AEs), and concomitant medica-
tions were recorded at each study visit
and during telephone calls between visits.
Events of nausea were recorded as spon-
taneous or solicited; only spontaneous
reports were included in this analysis. A
nausea evaluation questionnaire (e.g.,
nausea duration, timing, intensity, and
others factors) was completed for patients
who spontaneously reported nausea. Lab-
oratory samples including clinical chem-
istry, hematology, and antiexenatide
antibodies were collected at baseline and
at week 26 (or the early discontinuation
visit). Major hypoglycemia was deﬁned as
either any hypoglycemic episode with
symptoms consistent with hypoglycemia
that led to loss of consciousness or sei-
zure, with prompt recovery in response
to glucagon or glucose administration,
or documented hypoglycemia [plasma
glucose ,3.0 mmol/L (,54 mg/dL)]
requiring the assistance of another per-
son because of severe impairment in
consciousness or behavior (whether or
not symptoms of hypoglycemia were
detected by the patient). Minor hypogly-
cemia was deﬁned as symptoms of hypo-
glycemia that were treated by the patient
or resolved on their own, with docu-
mented plasma glucose ,3.0 mmol/L
(,54 mg/dL).
Patient-reported quality of life was
assessed at all visits from baseline on-
wards using the Psychological General
Well Being index (18) and Impact of
Weight on Quality of Life-Lite (19). Pa-
tients who withdrew from the study
completed these assessments at the dis-
continuation visit.
Outcomes
The primary objective of the study was to
compare the effect of 26 weeks of EQW
treatment to a titrated dosage of detemir
once daily or BID with respect to the com-
posite outcome of proportion of patients
achieving A1C #7.0% (53 mmol/mol)
and weight loss $1.0 kg at end point;
the cut-off of $1.0 kg was chosen to re-
ﬂect the variation in sequential measure-
ments of weight and the margin of error
for essentially no weight gain.
Secondary efﬁcacy outcomes reported
include the proportion of patients achiev-
ing the following: A1C #7.4% (#57
mmol/mol) with weight loss $1.0 kg at
end point; A1C #7.0% and #7.4% with
any weight change #1 kg at end point;
A1C #7.4%, #7.0%, and #6.5% (48
mmol/mol) at end point; changes in A1C
and body weight from baseline to end
point and from baseline to weeks 12, 18,
and 26; changes in FPG and cardiovascu-
lar risk parameters [BMI, waist circumfer-
ence, systolic blood pressure (SBP),
diastolic blood pressure (DBP), heart
rate, lipid proﬁles, plasminogen activator
inhibitor-1 (PAI-1), high-sensitivity C-
reactive protein (hs-CRP), and adiponec-
tin] from baseline to end point; and the
incidence of AEs. At the time the study
was designed, A1C of#7.4% was the rec-
ommended target in the United Kingdom
for reimbursement in general practice.
A1C values also were reported in Interna-
tional Federation of Clinical Chemistry
units (mmol/mol).
Statistical methods
A total of 170 patients (85 per treatment)
were required to provide 90% power to
detect a difference between treatments,
with 5% signiﬁcance, assuming the week
26 response rates (primary end point) were
50% in the EQW group and 25% in the
detemir group. The studywas not powered
for a noninferiority analysis. Likely response
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rates were based on results from previous
clinical trials (6–8). Assuming a drop-out
rate of 20% resulted in a ﬁnal overall sample
size of 214 patients.
The last observation carried forward
method was used for missing data for the
intent-to-treat (ITT) analysis; end point
was deﬁned as the last study visit (be-
tween and including the baseline and
week 26 visit). Study outcomes including
ﬁnal A1C concentration and change in
weight used the last postbaseline mea-
surement set of both nonmissing A1C
and weight (measured at the same visit).
All tests of treatment effects were con-
ducted at a two-sided a level of 0.05. CIs
were computed as two-tailed using 95%
level, and differences were based on the
EQW estimate minus the detemir esti-
mate.
Reasons for discontinuation and drop-
out rates were compared between treat-
ment groups using Fisher exact test. For
baseline characteristics, all categorical var-
iables were summarized using frequencies
and percentages, and continuous variables
were summarized using descriptive statis-
tics, including mean and SD.
The primary outcome was analyzed
for the ITT population (deﬁned as all
randomized patients who received at least
one dose of study drug) using a logistic
regression model that included treatment
group, use of SU, baseline A1C, and
baseline weight as main factors. Hypoth-
esis testing was based on the maximum
likelihood estimate for the treatment
main effect with corresponding 95% CI.
Secondary outcomes also were ana-
lyzed using the ITT population. Proportion
of patients achieving A1C concentration
#7.0% with weight loss $1.0 kg at 12
weeks, A1C #7.4% with weight loss
$1.0 kg at end point, A1C #7.0% and
#7.4% with weight change #1.0 kg at
end point, and A1C #7.4%, #7.0%, and
#6.5% were analyzed using the same
methods as the primary outcome. The in-
cidence of hypoglycemia was analyzed us-
ing logistic regression and categorized by
use of concomitant SU. Exposure-adjusted
incidence of hypoglycemia per 100 patient-
years was reported.
Continuous variables with repeated
measurements (A1C, body weight, BMI,
waist circumference, SBP, and DBP) were
evaluated using the likelihood-based
mixed model repeated measures (MMRM)
analysis that included the corresponding
baseline value as covariate; study treat-
ment, use of SU, baseline A1C, week of
visit, and treatment-by-week interaction
were ﬁxed effects; patient and error were
random effects. MMRM results are re-
ported as least-square (LS) mean (6 SE
and 95% CI). An ANCOVA model was
used for A1C, body weight, BMI, waist
circumference, SBP, DBP, FPG, heart
rate, lipid proﬁles, PAI-1, and adiponec-
tin, in which the dependent variable was
the last observation carried forward
change from baseline to end point and
independent variables were treatment
group, corresponding baseline value,
use of SU, and baseline A1C. LS means,
SE, and 95% CI were reported for treat-
ment group differences and differences
from baseline to end point. Change in
hs-CRP was analyzed using log transfor-
mation (ANCOVA model adjusted for
treatment, baseline log value of A1C,
use of SU, and corresponding baseline
value); values $10 mg/L were excluded.
Results are presented as geometric LS
mean ratios of baseline to end point and
EQW to detemir. The incidence of all
treatment emergent AEs and serious AEs
were summarized.
RESULTSdOf the 325 patients
screened, 222 patients were randomized
to treatment, 216 received at least one
dose of study drug (ITT population), and
191 completed the study to week 26 (Fig.
1). Demographics (Fig. 1) and baseline
characteristics (Table 1) were similar be-
tween groups. Because the majority of pa-
tients were Caucasian, assessments of
efﬁcacy related to ethnicity were not
made. Mean 6 SD exposure to treatment
was 23.7 6 6.5 weeks for EQW and
25.26 5.6 weeks for detemir. The starting
dose of insulin ranged from 2.0 IU/day
to 62.0 IU/day. The mean 6 SD daily
dose of detemir was initially 0.21 6 0.10
IU/kg per day (20.8 6 10.8 IU/day); this
increased to 0.51 6 0.3 IU/kg per day
(50.5 6 28.1 IU/day) at end point. Most
detemir-treated patients (89.5%) received
one insulin injection daily; the remainder
(10.5%) received two injections per day.
The proportion of detemir-treated patients
who achieved fasting blood glucose (self-
monitored blood glucose measured before
breakfast) of ,5.5 mmol/L at end point
was 17%.
All patients received concomitant
metformin (mean 6 SD: 1,940.3 6
550.9 mg) and 70% of EQW-treated pa-
tients and 72% of detemir-treated pa-
tients received a SU, including gliclazide
(59 and 56%), glibenclamide (1 and 0%),
glipizide (3 and 4%), glimepiride (6 and
10%), and sulphonamides/urea derivatives
(1 and 3%). Of the EQW-treated patients,
80% of patients decreased SU therapy by
end point, 4% discontinued, 15% had no
change, and 1% increased SU therapy.
Comparatively, in detemir-treated patients,
70% of patients decreased, none discontin-
ued, 30% had no change, and none in-
creased SU therapy by end point. Most
decreases in SU dose occurred at the start
of the study and involved decreasing the
dose by half. Other nonantidiabetes con-
comitant therapy also was used by most
patients, including antihypertensive medi-
cations (73%), ﬁbrates (6%), and statins
(83%).
Primary outcome
Forty-nine (44.1%; 95% CI, 34.7253.9)
patients in the EQW group and 12
(11.4%; 6.0–19.1) patients in the detemir
group achieved A1C #7.0% with weight
loss $1.0 kg at end point (Table 1). Lo-
gistic regression analysis showed that the
odds ratio for patients in the EQW group
achieving the primary outcome was 6.6
(3.2–13.7) compared with patients in
the detemir group (P , 0.0001). Use of
SU and baseline body weight did not
inﬂuence a patient’s chance of achieving
the primary outcome, but baseline A1C
did have an effect, with higher baseline
levels reducing the chance of achieving
A1C #7.0% with weight loss $1.0 kg
(P , 0.05).
Secondary outcomes
Glycemic control. Baseline A1C was
8.37 6 0.85% in the EQW group and
8.35 6 0.88% in the detemir group (Ta-
ble 1). At study end point, A1C values [LS
mean 6 SD (95% CI)] were 7.07 6
0.81% (6.91–7.22) in the EQW group
and 7.506 0.89% (7.32–7.67) in the de-
temir group [EQW, 53.7 6 8.9 mmol/
mol (52.0–55.4); detemir, 58.4 6 9.8
mmol/mol (56.5–60.3)]. Mean change
in A1C was signiﬁcantly greater with
EQW than with detemir as early as 12
weeks after treatment initiation (P ,
0.0001), and the difference was main-
tained to week 26 (P = 0.0001; Fig. 2A).
At end point, change in A1C [LS mean6
SE (95% CI)] in the ITT population was
21.30 6 0.08% (21.45 to 1.14) with
EQW and 20.88 6 0.08% (21.03 to
20.72) with detemir [P , 0.0001;
EQW,214.386 0.83 mmol/mol (216.01
to212.75); detemir,29.906 0.84 mmol/
mol (211.56 to28.24)]. Results were sim-
ilar for the ITT population and the 26-week
completer population (change in A1C for
ITT population shown in Fig. 2A).
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Other glycemic outcomes (target A1C
#7.4%, #7.0%, #6.5%, composite tar-
get A1C and weight loss, composite target
A1C and minimal weight gain) favored
EQW over detemir, with many of the
between-treatment differences showing
statistical signiﬁcance (Table 1 and Fig. 2B).
There was a signiﬁcant reduction in fasting
glucose from baseline in both treatment
groups [LS mean (95% CI): EQW 22.3
mmol/L (22.7 to 22.0) vs. detemir 22.4
mmol/L (22.8 to22.1); Table 1], but there
wasno signiﬁcantdifferencebetweengroups.
Fasting glucose levels measured by
7-point self-monitored blood glucose de-
creased signiﬁcantly from baseline to
end point at all time points in both groups.
The only signiﬁcant differences between
groups were in the prebreakfast (LS
mean 6 SE: EQW 21.9 6 0.2 mmol/L
vs. detemir 22.5 6 0.2 mmol/L; P =
0.014), postdinner (EQW 22.7 6 0.3
mmol/L vs. detemir 21.8 6 0.3 mmol/L;
P = 0.023), and bedtime (EQW 22.9 6
0.3 mmol/L vs. detemir 21.8 6 0.3
mmol/L; P = 0.005) measurements.
Cardiovascular risk factors. There was a
progressive decrease in body weight from
baseline at each visit in patients receiving
EQW; in contrast, body weight increased
in detemir-treated patients (Fig. 2C). At
end point, body weight, BMI, and waist
circumference were signiﬁcantly reduced
in the EQW group compared with the
detemir group (P , 0.0001; Table 1).
The change in body weight in EQW-
treated patients appeared unrelated to the
presence or absence of nausea, because pa-
tients without nausea lost (mean 6 SD)
2.7 6 3.3 kg compared with 2.8 6
3.3 kg in patients who did experience nau-
sea. Other speciﬁc measures of cardiovas-
cular risk were improved in both treatment
groups by study end (Table 1). Notably,
EQW treatment resulted in signiﬁcantly
greater improvements compared with
treatment with detemir in SBP (P ,
0.01), PAI-1 (P , 0.006), and hs-CRP
(P , 0.004) (Table 1). Individual patient
A1C at end point versus changes in weight
at end point are shown in Fig. 2D.
Figure 1dStudy population, disposition, and demographics.
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Patient-reported outcomes
Total scores on the Psychological General
Well-Being questionnaire showed im-
provement [LS mean 6 SE (95% CI)]
from baseline to week 26 for the EQW
group [+4.2 6 1.1 (2.0–6.5)] but not
the detemir group [+1.8 6 1.2 (20.6 to
4.1)], and there was no signiﬁcant differ-
ence between treatment groups. The total
scores for the Impact of Weight on Qual-
ity of Life-Lite questionnaire showed im-
provements from baseline to week 26
for both groups [LS mean: EQW +6.2 6
1.0 (95% CI, 4.2–8.2) compared with de-
temir +2.8 6 1.1 (0.7–4.9)], with signif-
icantly greater improvement in the EQW
group versus the detemir group (0.7–6.1;
P = 0.015).
Safety and tolerability
Overall, 103 (93%) EQW-treated patients
and 86 (82%) detemir-treated patients ex-
perienced at least one treatment-emergent
AE. Frequent AEs are shown in Table 2.
After nasopharyngitis and headache,
which were the most frequent AEs in
both groups, the most common AEs in
the EQW group were gastrointestinal-
related, with spontaneously-reported nau-
sea occurring in 18%of patients versus 2%
in the detemir group (Table 2). Vomiting
(17% vs. 11%) and diarrhea (14% vs. 9%)
were frequently reported in both treat-
ment groups (EQW vs. detemir). Evalua-
tion of nausea events showed that nausea
was mild to moderate in intensity and
Table 1dBaseline characteristics and treatment effects (baseline to end point) of EQW or insulin detemir
Variable EQW (n = 111) Insulin detemir (n = 105)
Baseline characteristic, mean 6 SD
A1C, % 8.37 6 0.85 8.35 6 0.88
A1C, mmol/mol 67.9 6 9.3 67.8 6 9.6
Fasting glucose, mmol/L 9.8 6 2.4 9.8 6 2.3
Weight, kg 96.7 6 17.0 97.9 6 15.8
BMI, kg/m2 33.7 6 4.7 33.7 6 4.7
Waist circumference, cm 110.9 6 12.0 110.4 6 11.8
SBP, mmHg 134.4 6 16.5 138.1 6 17.4
DBP, mmHg 78.8 6 9.5 80.1 6 10.3
Heart rate, bpm 74.1 6 9.9 74.5 6 11.7
Primary outcome, % patients (95% CI) at end point Odds ratio (95% CI)*
A1C #7% and weight loss $1.0 kg† 44.1 (34.7–53.9) 11.4 (6.0–19.1) 6.6 (3.2–13.7)‡
Secondary outcomes, % patients (95% CI)
A1C #7% and weight loss $1.0 kg at 12 weeks 38.6 (29.1–48.8) 10.3 (5.1–18.1) 7.0 (3.0–16.0)‡
A1C #7.4% with weight loss $1.0 kg 58.9 (49.0–68.3) 17.8 (10.9–26.7) 7.1 (3.6–13.7)‡
A1C #7.0% with minimal weight gainx 53.3 (43.4–63.0) 17.8 (10.9–26.7) 6.3 (3.2–12.6)‡
A1C #7.4% with minimal weight gainx 66.4 (56.6–75.2) 25.7 (17.6–35.4) 6.8 (3.5–13.2)‡
Secondary outcomes, LS mean change (95% CI){ Treatment difference (95% CI)
A1C, % 21.30 (21.45 to 21.14) 20.88 (21.03 to 20.72) 20.42 (20.63 to 20.21)‡
A1C, mmol/mol 214.38 (216.01 to 212.75) 29.90 (211.56 to 28.24) 24.48 (26.73 to 22.24)
Fasting plasma glucose, mmol/L 22.3 (22.7 to 22.0) 22.4 (22.8 to 22.1) +0.1 (20.4 to 0.6)
Body weight, kg 22.7 (23.4 to 22.0) +0.8 (0.1–1.5) 23.5 (24.4 to 22.6)‡
BMI, kg/m2 21.0 (21.2 to 20.7) +0.3 (0.02–0.5) 21.3 (21.6 to 20.9)‡
Waist circumference, cm 22.3 (23.3 to 21.4) +1.1 (20.1 to 2.1) 23.4 (24.8 to 22.1)‡
SBP, mmHg 26.8 (29.4 to 24.2) 22.4 (25.0 to 0.3) 24.4 (27.9 to 21.0)|
DBP, mmHg 20.4 (22.1 to 1.3) 20.3 (22.1 to 1.4) 20.1 (22.4 to 2.2)
Heart rate, bpm +5.5 (3.5–7.4) 20.8 (22.7 to 1.1) 6.2 (3.7–8.8)**
Total cholesterol, mmol/L 20.1 (20.2 to 0.04) +0.1 (20.1 to 0.2) 20.2 (20.3 to 0.03)
LDL cholesterol, mmol/L 20.1 (20.2 to 20.01) +0.03 (20.1 to 0.1) 20.2 (20.3 to 0.0)
HDL cholesterol, mmol/L +0.02 (20.01 to 0.05) +0.04 (0.01–0.1) 20.01 (20.05 to 0.02)
Triglycerides, mmol/L 20.01 (20.2 to 0.2) 20.1 (20.2 to 0.1) +0.1 (20.1 to 0.3)
Adiponectin, ng/mL +40.0 (2236.7 to 316.6) +48.2 (2229.9 to 326.3) 28.2 (2379.4 to 362.9)
PAI-1, IU/mL 212.1 (216.8 to 27.5) 23.4 (28.1 to 1.2) 28.7 (214.9 to 22.5)††
hs-CRP, mg/L‡‡ +0.8 (0.7–0.9)xx +1.1 (0.9–1.2)xx +0.7 (0.6–0.9){{
Baseline characteristics include patients with available data (EQW, insulin detemir). Proportions are percentages based on the ITT population (95% CI). ANCOVA
analyses are presented as LSmean (SE, 95%CI) for change at end point. *Logistic regression analysis. †Includes patients withmissing data (i.e., nonresponders; EQW,
n = 111; insulin detemir, n = 105). ‡P , 0.0001. xMinimal weight loss #1 kg. {ANCOVA method used for secondary outcomes. |P = 0.0130. **P , 0.05. ††P =
0.0062. ‡‡hs-CRP values $10 mg/dL excluded, results presented as geometric LS mean ratio (95% CI). xxRatio of baseline to end point. {{Ratio of exenatide to
detemir, P = 0.004.
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generally improved after eating a meal.
Injection-site reactions, including injection-
site pruritus (11%) and injection-site nod-
ules (20%), were frequently reported in the
EQW group compared with the detemir
group (1 and 0%, respectively). Treatment-
emergent AEs led to study discontinuation
in 11% of EQW-treated patients and in 5%
of detemir-treated patients. The most com-
mon AEs leading to withdrawal were
injection site–related AEs (injection site–
related erythema, nodule, pruritus, urti-
caria, or other reaction) in both groups
(EQW 2% compared with detemir 4%)
and gastrointestinal-related AEs (nausea)
in the EQW group (2% vs. no discontin-
uations in the detemir group). Serious AEs
were reported by 5% of EQW-treated pa-
tients and in 6% of detemir-treated pa-
tients. No patient died as a result of an
AE in either group.
No patients experienced major hypo-
glycemia. Five patients (5% or 9.9 per 100
patient-years) in the EQW group and 6
patients (6% or 17.8 per 100 patient-
years) in the detemir group experienced
at least one episode of minor hypoglyce-
mia (Table 2); there was no difference in
incidence of hypoglycemia between
groups. One case of hypoglycemia in
each group was nocturnal. Only one pa-
tient experienced hypoglycemia without
concomitant SU use (detemir group).
At baseline, two (2%) patients in the
EQW group had antiexenatide antibodies
(all low titers of ,625). By end point, 64
(58%) patients in the EQW group were
antibody-positive, of whom 52 (81.3%)
patients had low titers and 12 (19%)
had higher titers ($625); 38 (42%) pa-
tients were antibody-negative. Although
changes in A1C were variable among
patients with positive titers (23.5% to
+1.2%), the change in A1C was lower in
patients with higher titers (LS mean,
20.7%; 95%CI,21.0 to 0) than in patients
with low titers (21.4%; 21.6 to 21.1) or
whowere antibody-negative (21.3%;21.6
to21.1).
CONCLUSIONSdThe results of this
study comparing EQW with detemir in
patients with type 2 diabetes who did not
achieve adequate glycemic control with
lifestyle modiﬁcations and OADs showed
that additional therapy with EQW pro-
vided better glycemic and weight control
compared with addition of detemir. For
the primary outcome, patients who re-
ceived EQW were 6.6-times more likely
to achieve A1C #7.0% with weight loss
$1.0kg thanpatientswho receiveddetemir.
Overall, 44.1% and 11.4% of patients in
Figure 2dChange in glycemic control and body weight at end point and at speciﬁc time points over 26 weeks of treatment with EQW or insulin
detemir (ITT population). A: LS mean6 SE change in A1C at 12, 18, and 26 weeks (MMRM used for analysis; data include patients with available
data) and at end point (ANCOVA and last observation carried forwardmethod used for analysis of change from baseline to end point). P indicated for
treatment differences. *P, 0.0001. B: Proportion of patients who achieved target A1C of#7.4%,#7.0%, and#6.5%. C: LS mean6 SE change in
body weight at weeks 4 to 26 and at end point (statistical methods same as those used for change in A1C); P indicated for treatment differences. *P =
0.0008 and **P , 0.0001. D: Scatter plot of A1C compared with change in weight at end point.
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each treatment group, respectively, achieved
the composite primary outcome. A greater
proportion of patients treated with EQW
also achieved A1C#7.4% with weight loss
and A1C targets of #7.4%, #7.0%, and
#6.5% compared with insulin detemir.
Consideration of treatment options
for patients with type 2 diabetes not
adequately controlled with metformin or
metformin and SU should take into ac-
count the potential advantage of weight
loss or weight neutrality in individual
patients (1). Therefore, a combination of
glycemic control with weight loss was se-
lected as a clinically relevant primary end
point, and insulin detemir was chosen as
an appropriate comparator for EQW be-
cause it is a long-acting insulin analog that
has been associated with less weight gain
than NPH insulin or insulin glargine (12–
15,20). EQW treatment resulted in signif-
icantly greater improvements compared
with treatment with detemir in A1C (as
early as 3 months) and body weight (as
early as 4 weeks), and these improve-
ments were maintained throughout the
trial. Further, measures of psychological
well-being andweight-related quality of life
were improved inboth groups,with greater
improvements in weight-related assess-
ments with EQW compared with detemir.
The present results build on previous
experience comparing exenatide with in-
sulins. Despite treatment with OADs and
insulin, the majority of patients with type
2 diabetes have difﬁculty achieving or
maintaining target glycemic control with-
out associated weight gain (21,22). Initi-
ating insulin therapy is often the next
step, but many patients still do not ach-
ieve optimal glycemic control with insu-
lin, partly because of weight gain (22).
Exenatide BID has been shown to be
more effective than insulin glargine for
improving the composite outcomes of
glycemic control with minimal weight
gain when used as add-on therapy in over-
weight patients at high risk for cardiovas-
cular disease and with type 2 diabetes
inadequately controlled by two or three
OADs (23). In another trial, exenatide
BID and insulin glargine similarly reduced
A1C levels and similar proportions of pa-
tients in each treatment group achieved
A1C targets, but weight was signiﬁcantly
lower in exenatide-treated patients (24).
EQW also recently has been com-
pared with insulin glargine in patients
with type 2 diabetes suboptimally con-
trolled using maximum tolerated doses of
OADs (7). EQW produced signiﬁcantly
greater reductions in A1C than insulin
glargine (LS mean, 21.5 vs. 21.3%) at
26 weeks and signiﬁcantly more patients
who received EQW achieved target A1C
#6.5% (43% vs. 28%). Additionally, at
26 weeks, treatment with EQW resulted in
mean reduction in body weight of22.6 kg
compared with an increase of 1.4 kg with
insulin glargine (P , 0.001) (7). At 84
weeks, patients treated with EQW contin-
ued to have signiﬁcantly greater reduc-
tions in A1C from baseline than those
who received insulin glargine (LS mean,
21.16 vs. 20.98%) and the difference in
body weight between groups was main-
tained (25).
The current study also measured the
effects of EQW and detemir on a number
of risk factors for cardiovascular disease.
Both treatments were associated with
improvements in several markers of car-
diovascular risk from baseline, with EQW
treatment resulting in signiﬁcantly greater
improvements in SBP, PAI-1, and hs-CRP
than with detemir treatment. There was a
signiﬁcant improvement from baseline in
LDL cholesterol in EQW-treated patients
and in HDL cholesterol in detemir-treated
patients, although the differences be-
tween treatments were not signiﬁcant.
Similarly, studies by Drucker et al. (6)
and Davies et al. (23) have shown im-
proved lipid proﬁles and SBP with EQW
and exenatide BID; effects on lipids and
SBP also were maintained after 3 years of
follow-up in a study by MacConell et al.
(26). The increase in heart rate observed
in patients treated with EQW was consis-
tent with increases seen in previous trials
(25,27), although the signiﬁcance of this
increase is unknown. The underlying
mechanisms of these effects have yet to
be established, and potential cardiovascu-
lar effects of EQW are undergoing inves-
tigation in an ongoing prospective trial
(EXSCEL).
The incidence of hypoglycemia was
generally low with both treatments in the
present trial, especially without concomi-
tant SU use. The incidence of hypoglyce-
mia was not different between the EQW
and detemir groups, which differs from
previous trials that compared insulin with
GLP-1 receptor agonists (7,28,29). How-
ever, other trials showed inconsistent re-
sults, including a lower incidence of
hypoglycemia with exenatide BID versus
Table 2dSafety and tolerability of 26 weeks of EQW or insulin detemir
Variable
EQW
(N = 111)
Insulin detemir
(N = 105)
Incidence of adverse events
At least 1 serious adverse event 6 (5) 6 (6)
Adverse event resulting in treatment discontinuation 12 (11) 5 (5)
Frequent adverse events (.5% of patients)
Nasopharyngitis 23 (21) 31 (30)
Headache 23 (21) 15 (14)
Injection-site nodule 22 (20) 0
Nausea* 20 (18) 2 (2)
Diarrhea 19 (17) 11 (11)
Vomiting 16 (14) 9 (9)
Injection-site pruritus 12 (11) 1 (1)
Constipation 10 (9) 3 (3)
Back pain 9 (8) 7 (7)
Musculoskeletal pain 7 (6) 2 (2)
Dyspepsia 7 (6) 1 (1)
Cough 7 (6) 9 (9)
Pain in extremity 6 (5) 3 (3)
Malaise 6 (5) 2 (2)
Lower respiratory tract infection 5 (4) 6 (6)
Arthralgia 5 (4) 6 (6)
Oropharyngeal pain 4 (4) 8 (7)
Hypoglycemia
Patients with $1 episode, n (%) 5 (5) 6 (6)
With SU 5 (6) 5 (7)
No SU 0 1 (3)
Data are n (%) patients. All episodes of hypoglycemia were minor (nomajor hypoglycemia). *Nausea includes
spontaneously reported events only.
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insulin aspart (28,30) or EQW (7) versus
insulin glargine, and no difference between
exenatide BID (23) or liraglutide (31) versus
insulin glargine. Furthermore, the incidence
of hypoglycemia with detemir (5.7% over-
all) was lower than the incidence reported in
other trials of detemir (conﬁrmedminor hy-
poglycemia, 16% to 56%) (12,32–35).
However, the current study was not pow-
ered for an assessment of hypoglycemia, and
the small number of events reported limits
potential inferences that can be drawn from
these data.
As has been reported previously, the
most common adverse event experienced
by EQW recipients was nausea. However,
this event did not appear to be associated
with additional weight loss and few pa-
tients discontinued the study because of
nausea. The incidence of nausea with
EQW in this study (18%) was similar to
the incidence reported in other trials
(11% to 26%) (5–8,27). Approximately
half of the patients were antibody-positive
for exenatide, most of whom had low tit-
ers. Overall, change in A1C was lower in
patients with higher titers than in patients
with low titers or those who were anti-
body-negative; however, antibody titers
were not predictive of individual A1C
changes, as previously reported (36).
A limitation of this study was that
forced titration of detemir was not strictly
enforced and patients reduced the dosage if
hypoglycemia occurred, leading to a mean
titrated dose of detemir at end point 0.51
IU/kg, which is at the lower end of the
range of mean doses of detemir used in
other trials of type 2 diabetes (0.4 to 0.9
IU/kg) (12,15,16,33,35,37–40). Conse-
quently, lower than average insulin doses
may have affected the potential magnitude
in A1C change or masked treatment-
related differences in hypoglycemia events.
This trial is the ﬁrst to compare EQW
and insulin detemir, which is associated
with less weight gain than other insulins.
The results showed that treatment with
EQW resulted in a signiﬁcantly greater
proportion of patients achieving target
A1C than with insulin detemir, with the
added beneﬁt of weight loss not seen with
detemir. We conclude that EQW repre-
sents an alternative treatment option to
insulin therapy in patients with type 2
diabetes using OADs with inadequate
glycemic control.
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